Metastatic carcinoma is the most common neoplasm involving the skeletal system. It is estimated that 30% to 70% of newly diagnosed cancer patients develop osseous metastases, causing intractable bone pain. A variety of treatments have been used to control bone pain associated with skeletal metastases, including analgesics, cytotoxic chemotherapy, external beam radiotherapy and systemic radio-nuclide therapy. Strontium 89 (89Sr) is a systemic radionuclide and calcium analog that has been extensively used for pain control in advanced skeletal metastatic disease. Strontium 89 offers advantages over other treatment modalities, including repeated treatments if necessary, less bone marrow suppression and toxicity and potential for cost effectiveness.
Get full access to this article
View all access options for this article.
References
1.
Malawer MM,Delanet TFPrinciples & Practice of Oncology. 4th edn.VT DeVitaHellman SRosenberg SA, ed. Philadelphia: Lippincott; 1993:2225-2244.
2.
Clain A.Secondary malignant disease of bone.Br J Cancer. 1965;19:15-20
3.
Abrams HL,Spiro R,Goldstein N.Metastases in carcinoma: Analysis of 1000 autopsied cases.Cancer. 1950;23:74-85
4.
Nightengale B,Brune M,Parkman Blizzard S.Strontium chloride Sr 89 for treating pain from metastatic bone disease.AJHP. 1995;52:2189-2195
5.
Diener KM.Bisphosphonates for controlling pain from metastatic bone disease.AJHP. 1996;53:1917-1927
6.
Reiner WG,Scott WW,Eggleston JE,Walsh PC.Long-term survival after hormonal therapy for stage D prostatic cancer.J Urol. 1979;122:183-190
7.
Byar DP.The Veterans Administration Cooperative Urological Research Group studies of cancer of the prostate.Cancer. 1973;32:1126-1130
8.
Warner B,Worgul TJ,Drago J.Effect of very high dose D-leucine-6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.J Clin Invest. 1983;71:1842-1848
9.
Early Breast Cancer Trialist's Collaborative Group (EBCTCG): Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer.N Engl J Med. 1988;319:1681-1692
10.
Tong D,Gillick L,Hendrickson FR.The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group.Cancer. 1982;50:893-899
11.
Blitzer PH.Reanalysis of the RTOG study of the palliation of symptomatic osseous metastases.Cancer. 1985;55:1468-1472
12.
Allen KL,Johnson TW,Hibbs GG.Effective bone irradiation as related to various treatment regimens.Cancer. 1976;37:984-987
13.
Hoskin PJ,Price P,Easton D.A prospective randomized trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain.Radiother Oncol. 1992;23:74-78
14.
Salazar OM,Rubin P,Hendrickson FR.Single-dose half-body irradiation for palliation of painful bone metastases from solid tumors: Final Radiation Therapy Oncology Group report.Cancer. 1986;58:29-37
15.
Kuban DA,Delbridge T,El-Mahdi AM,Schellhammer PF.Half-body irradiation for treatment of widely metastatic adenocarcinoma of the prostate.J Urol. 1989;141:572-574
16.
Zalefsky MJ,Scher HI,Forman JD.Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: A comparison of single dose and fractionated regimens.Int J Radiat Oncol Biol Phys. 1989;17:1281-1285
17.
Goethuys H,Baert L,Poppel Van H.Treatment of metastatic carcinoma of the prostate.Am J Clin Oncol.. 1997;20:40-45
18.
Porter AT,Ben-Josef EImportant Advances in Oncology. DeVita VTHelman SRosenberg SA, ed. Philadelphia: Lippincott; 1995:87-94.
19.
Atkins HL,Mausner LF,Srivastava SC.Biodistribution of Sn-117m (4+) DTPA for palliative therapy of painful osseous metastases.Radiology. 1993;186:279-283
20.
Mitchell JB,Bedford JS,Bailey SM.Dose-rate effects on the cell cycle and survival of S3 HeLa and V79 cells.Radiat Res. 1979;79:537-551
21.
Lewington VJ,McEwan AJ,Ackery DM.A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone.Eur J Cancer. 1991;27:954-958
22.
Porter AT,McEwan AJB,Powe JE.Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant prostate cancer.Int J Radiation Oncology Biol Phys. 1993;25:805-813
23.
Quilty PM,Kirk D,Bolger JJ.A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer.Radiother Oncol. 1994;31:33-40
24.
Robinson RG,Blake GM,Preston DF.Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone.Radiographies. 1989;9:271-281
25.
Laing AH,Ackery DM,Bayly RJ.Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.Br J Radiology. 1991;64:816-822
26.
Fossa SD,Paus E,Lichoff M.89-Strontium inbone metastases from hormone resistant prostate cancer: Palliation effect and biochemical changes.Br J Cancer. 1992;64:177-180
27.
Powsner RA,Zietman AL,Foss FM.Bone marrow suppression after strontium-89 therapy and local radiation therapy in patients with diffuse marrow involvement.Clin Nuc Med. 1997;22:147-150
28.
Gilbert HA,Kagan AR,Nussbaum H.Evaluation of radiation therapy for bone metastases: Pain relief and quality of life.AJR. 1977;129:1095-1096
29.
McEwan AJB,Amyotte GA,McGowan DG.A retrospective analysis of the cost effectiveness of treatment with Metastron (Sr-89 chloride) in patients with prostate cancer metastatic to bone.Nuc Med Comm. 1994;15:499-504
30.
Robinson RG,Preston DF,Schiefelbein M,Baxter K.Strontium 89 therapy for the palliation of pain due to osseous metastases.JAMA. 1995;274:420-424
31.
Papatheofanis FJ,Yeung DW.Pharmacoeconomic benefits of SR-89 therapy for the treatment of symptomatic osseous metastases.J Nuc Med (abstract). 1996;37:116
32.
Drug Topics: Read Book. Montvale, NJ: Medical Economics Company, Inc.; 1997:
33.
Sciuto R,Maini CL,Tofani A.Radiosensitization with low-dose caroplatin enhances pain palliation in radioisotope therapy with strontium-89.Nuclear Med Comm.. 1996;17:799-804
